Epalinges, Switzerland/Los Angeles, California (USA) – June 30, 2025 – ASPIVIX is pleased to announce a new partnership with AGHealth to launch Carevix®, its MHRA-approved non-traumatic suction cervical stabilizer, in the United Kingdom. This milestone marks a significant advance in UK women’s healthcare, offering a modern and clinically validated alternative to the traditional cervical tenaculum.

Carevix®, approved for use by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), has been designed to minimize pain and reduce bleeding during intrauterine procedures such as coil-fitting and endometrial biopsies. Traditional tenaculum forceps—still commonly used—are known to cause discomfort, fear, and sometimes trauma for patients.

Peterborough City Hospital, part of the North West Anglia NHS Foundation Trust, became the first hospital in the UK to adopt Carevix® in 2024 through the Carevix® Ambassador Program. This initiative brought together 21 centers of excellence across 9 countries to evaluate the device in real-world settings. Results from the program showed high satisfaction among both clinicians and patients, with 96% of clinicians finding Carevix® easy to use and 94% overall patient satisfaction (1).

Fear of pain during IUD insertion remains a major barrier to adoption, affecting 30% to 45% of women globally, an estimated 120 million women each year, primarily due to the use of the traditional cervical tenaculum. In addition to the Ambassador Program, the ADVANCE Women Study, a single-blinded, randomized, multicenter comparative trial showed that Carevix® demonstrated a 73% reduction in pain and 78% reduction in bleeding during IUD placement compared to the standard tenaculum, becoming a new alternative for better patient experience.

AGHealth, a UK specialist distributor in women’s health, is known for introducing evidence-based, clinically relevant innovations to NHS and private sector providers. With a strong network and a mission to improve women’s healthcare, AGHealth is an ideal partner for ASPIVIX as it scales its presence in the UK.

Charlotte Barker, Director of AGHealth shares “At AGHealth, we focus on delivering forward-thinking, evidence-based solutions to clinicians. Carevix® represents exactly the kind of innovation the UK market needs—offering a more dignified, pain-conscious option for gynaecological procedures that women undergo every day. ”

Mathieu Horras, ASPIVIX CEO & Co-Founder, adds “We are proud to bring Carevix® to the UK in partnership with AGHealth, a company that shares our commitment to advancing women’s health through innovation. With MHRA approval and strong clinical results, Carevix® provides a game-changing solution that improves both patient comfort and clinical confidence. ”

With this new collaboration, ASPIVIX expands its footprint while strengthening its mission to modernise gynaecology and empower women with better choices.

About Aspivix
Aspivix is a pioneering leader in women’s health, dedicated to modernizing healthcare solutions for women around the world. Focused on innovation, Aspivix is committed to develop cutting-edge medical devices, such as carevix®, designed to transform the gynecological experience by offering safer and less painful solutions that enhance the quality of care and empower women to take control of their health.

About AGHealth
AGHealth is a UK-based specialist distributor with a strong portfolio in women’s health. With a focus on clinically proven, high-quality medical devices, AGHealth works closely with NHS and private sector providers to introduce innovations that improve outcomes and elevate patient experience. The company is known for its commitment to advancing gynaecological care through education, support, and strategic partnerships.

Information at www.aghealth.co.uk/post/carevix-now-available-to-uk-clinics

For media inquiries or more information :

Please contact: Ikram Guerd – VP of Global Marketing: ikram.guerd@aspivix.com.